AdKhabar

AdKhabar AdKhabar is an Indian search advertising Platform is a part of “lifecarenews” is based in Rajkot

Bionomics Limited Announces Private Placement of up to
02/06/2024

Bionomics Limited Announces Private Placement of up to

ADELAIDE, Australia and CAMBRIDGE, Mass., May 31, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (“Bionomics” or the “Company”), a clinical-stage biotechnology company developing novel, potential first-in-class, allosteric ion channel modulators to treat patients suffering from se...

Generation Lab Introduces First Platform that Measures
02/06/2024

Generation Lab Introduces First Platform that Measures

SAN FRANCISCO, May 31, 2024 (GLOBE NEWSWIRE) -- Generation Lab, the first longevity platform to measurably extend the human lifespan, today announced the general availability of its groundbreaking offering: the first platform that measures aging speed, biomarkers for disease, and top aging factors.....

Lipella Pharmaceuticals Announces Completion of Site
02/06/2024

Lipella Pharmaceuticals Announces Completion of Site

Clinical testing of LP-310 expected to commence in mid-2024 Patient recruitment is underway for Phase 2a multicenter, dose-ranging study PITTSBURGH, May 31, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella,” “our,” “us” or the “Company”), a clinical-stag...

Milestone® Pharmaceuticals to Participate in the Upcoming
02/06/2024

Milestone® Pharmaceuticals to Participate in the Upcoming

MONTREAL and CHARLOTTE, N.C., May 31, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced that members of its management team will participate in the Jefferies Global Healthcare Conference being held in New York City, NY from June 4-6, 2024. Management will parti...

SS Innovations Engages BDO as its new Auditor
02/06/2024

SS Innovations Engages BDO as its new Auditor

FORT LAUDERDALE, Fla., May 31, 2024 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the “Company” or “SS Innovations”) (OTC: SSII), a developer of innovative surgical robotic technologies dedicated to making world class robotic surgery affordable and accessible to a global population...

Morphic to Participate in Jefferies Global Healthcare
02/06/2024

Morphic to Participate in Jefferies Global Healthcare

WALTHAM, Mass., May 31, 2024 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that members of its management team will take part in a fireside chat at....

Aptose Announces $4.43 Million Registered Direct Offering
02/06/2024

Aptose Announces $4.43 Million Registered Direct Offering

SAN DIEGO and TORONTO, May 31, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today announced that it h...

Immunocore presents KIMMTRAK clinical data demonstrating
01/06/2024

Immunocore presents KIMMTRAK clinical data demonstrating

Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response Data were presented at ASCO 2024, where Immunocore also presented Phase 1 data from its PRAME trial with brenetafu...

Kymera Therapeutics Presents New Clinical Data from Ongoing
01/06/2024

Kymera Therapeutics Presents New Clinical Data from Ongoing

KT-253 demonstrates initial clinical proof of concept in patients with tumor types shown to be sensitive in preclinical models, including responses in MCC and AML Evidence of target engagement and potent upregulation of p53 pathway biomarkers even at the lowest dose levels in solid tumor and AML pat...

Y-mAbs Announces New Interim Analysis of Phase 2 Data for
01/06/2024

Y-mAbs Announces New Interim Analysis of Phase 2 Data for

NEW YORK, June 01, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatmen...

ClearPoint Neuro Announces Full Market Release of
01/06/2024

ClearPoint Neuro Announces Full Market Release of

SOLANA BEACH, Calif., June 01, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announces full market release of its SmartFrame OR platform and ClearP...

Black Diamond Therapeutics Presents Promising BDTX-1535
01/06/2024

Black Diamond Therapeutics Presents Promising BDTX-1535

Results from Phase 1 dose escalation trial of BDTX-1535 in GBM patients demonstrated a favorable safety and tolerability profile, and encouraging anti-tumor activity and duration of treatment Initial data from Phase 0/1 “trigger” (“window of opportunity”) investigator-sponsored trial demonst...

Affimed Provides Follow-up Data of AFM24 plus Atezolizumab
01/06/2024

Affimed Provides Follow-up Data of AFM24 plus Atezolizumab

In 17 EGFR wild-type (EGFRwt) non-small cell lung cancer (NSCLC) patients who failed chemotherapy and PD-1/PD-L1, AFM24 plus atezolizumab achieved 4 objective responses; 3 of 4 responses were ongoing for more than 7 months and progression free survival (PFS) was 5.9 monthsObjective responses were al...

SYS6002 (CRB-701) A Next-Generation Nectin-4 Targeting
01/06/2024

SYS6002 (CRB-701) A Next-Generation Nectin-4 Targeting

An additional 19 patients have been enrolled since January 2024 bringing the total to 37 of whom 25 were evaluable for efficacySYS6002 (CRB-701) demonstrated 44% ORR and 78% DCR in mUC and 43% ORR and 86% DCR in cervical cancer to date at doses ≥ 1.2mg/KgNo dose limiting toxicities (DLTs) have…

Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in
01/06/2024

Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in

Initial data from the ongoing Phase 2 trial showed a 12-month overall survival rate of 69% and a median overall survival of 17.5 months in patients with previously treated PD-L1-positive metastatic non-small cell lung cancer treated with a combination of acasunlimab and pembrolizumab every six weeks...

Werewolf Therapeutics to Present Data from Ongoing Phase
01/06/2024

Werewolf Therapeutics to Present Data from Ongoing Phase

- WTX-124 was shown to be clinically active and generally well-tolerated in patients who were relapsed/refractory to immune checkpoint inhibitor therapy - - Encouraging single agent clinical activity with three objective responses, including a durable confirmed complete response - - Monotherapy reco...

Y-mAbs Announces Publication of Preclinical GD2-SADA Data
01/06/2024

Y-mAbs Announces Publication of Preclinical GD2-SADA Data

NEW YORK, June 01, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatmen...

Cullinan Therapeutics Announces Positive Initial Data from
01/06/2024

Cullinan Therapeutics Announces Positive Initial Data from

CAMBRIDGE, Mass., June 01, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced positive initial data in patients receiving zipalertinib after prior treatment with amivantamab enro...

Autonomix Medical, Inc. Reports Full Year 2024 Financial
01/06/2024

Autonomix Medical, Inc. Reports Full Year 2024 Financial

Year marked by operational and clinical ex*****on advancing the development of a potential breakthrough technology for the nervous system Continued progress in first study ever to evaluate radiofrequency (RF) ablation in a transvascular approach to reduce the pain associated with pancreatic cancer T...

AIM ImmunoTech Announces Pricing of $2.0 Million Registered
01/06/2024

AIM ImmunoTech Announces Pricing of $2.0 Million Registered

OCALA, Fla., May 31, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase 5,640,958 shares of common stock in a registered direct of...

Sharps Technology’s SC Asset Purchase and $200 Million
01/06/2024

Sharps Technology’s SC Asset Purchase and $200 Million

Sharps CEO issues letter to shareholders with details about the InjectEZ acquisition, establishing Sharps position in the prefillable syringe (PFS) industry in the U.S. Signed Syringe Sales Agreement will secure product orders totaling over $200 million for the first five years of operation. Sharps....

JDRF Walk to Cure Diabetes
01/06/2024

JDRF Walk to Cure Diabetes

TORONTO, May 31, 2024 (GLOBE NEWSWIRE) -- The JDRF Walk to Cure Diabetes is the largest fundraising event in Canada that brings together the type 1 diabetes (T1D) community to raise funds for T1D research. A fun-filled family and community celebration, the Walk has raised more than $140 million to.....

Zealand Pharma announces positive CHMP opinion for
01/06/2024

Zealand Pharma announces positive CHMP opinion for

Press release – No. 6 / 2024 Zealand Pharma announces positive CHMP opinion for dasiglucagon for treatment of severe hypoglycemia in diabetes from European Medicines Agency Copenhagen, Denmark, May 31, 2024 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused o...

AB Science is providing a summary of the live webcast held
01/06/2024

AB Science is providing a summary of the live webcast held

PRESS RELEASE SUMMARY OF THE WEBCAST HELD ON MAY 30, 2024, PROVIDING AN UPDATE ON THE APPLICATION FOR CONDITIONAL MARKETING AUTHORISATION OF MASITINIB IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS Paris, May 31, 2024, 4.30pm CET AB Science SA (Euronext - FR0010557264 - AB) is providing a summary...

01/06/2024

Bavarian Nordic Submits Supplemental BLA Seeking U.S. FDA

COPENHAGEN, Denmark, May 31, 2024 – Bavarian Nordic A/S (OMX: BAVA) today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval of a freeze-dried formulation of JYNNEOS® for prevention of smallpox and mpox d...

Immunocore reports updated Phase 1 data of brenetafusp
01/06/2024

Immunocore reports updated Phase 1 data of brenetafusp

Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024 Monotherapy brenetafusp (IMC-F106C) in late-line cutaneous melanoma demonstrated promising disease control (partial resp...

CENTOGENE Announces Adoption of All Resolutions Tabled at
01/06/2024

CENTOGENE Announces Adoption of All Resolutions Tabled at

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, May 31, 2024 (GLOBE NEWSWIRE) -- CENTOGENE N.V. (Nasdaq: CNTG) (the “Company”), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced the voting results of the Company’s 2024 Annual G...

Mainz Biomed Reports Results of 2024 Annual General
01/06/2024

Mainz Biomed Reports Results of 2024 Annual General

BERKELEY, Calif. and MAINZ, Germany, May 31, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ: MYNZ), a molecular genetics diagnostic company specializing in the early detection of cancer, held its annual general meeting (“Annual General Meeting”) on Friday, May 31, 2024 in Amsterdam, The Neth...

RYBREVANT®▼ (amivantamab) plus lazertinib shows longer
31/05/2024

RYBREVANT®▼ (amivantamab) plus lazertinib shows longer

Investigational chemotherapy-free regimen of amivantamab plus lazertinib addresses a significant unmet need as most patients with EGFR-mutated NSCLC have high-risk disease1 Landmark Phase 3 MARIPOSA data featured in an oral presentation at ASCO1 BEERSE, BELGIUM, May 31, 2024 (GLOBE NEWSWIRE) -- Jans...

Johnson & Johnson submits application to the European
31/05/2024

Johnson & Johnson submits application to the European

Submission is supported by data from the Phase 3 PALOMA-3 study featured at the American Society of Clinical Oncology (ASCO) Annual Meeting1 New formulation showed non-inferiority to intravenous administration in fourth positive Phase 3 amivantamab study1 Longer overall survival, progression-free su...

Address


Alerts

Be the first to know and let us send you an email when AdKhabar posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to AdKhabar:

Videos

Shortcuts

  • Address
  • Telephone
  • Alerts
  • Contact The Business
  • Videos
  • Claim ownership or report listing
  • Want your business to be the top-listed Media Company?

Share